Radiolabelling studies facilitated optimisation of the molecular structures of α-MSH analogues for tumour uptake, such as substituting lysine for arginine in the peptide sequence and replacing the conjugate lysine D-enantiomer. The gene discussed is STAMBP; the disease is neoplasm.